An investigation of the traditional algorithm-based designs for phase 1 cancer clinical trials

Seung Ho Kang, Chul W. Ahn

Research output: Contribution to journalArticle

Abstract

The primary aim of a phase 1 cancer clinical trial is to determine the maximum tolerated dose of a new drug. Although the continual reassessment method is shown to have better operating characteristics than traditional designs, traditional designs are still widely used in practice. Kang and Ahn (1) developed an algorithm to compute the exact distribution of the maximum tolerated dose (MTD) in traditional designs with dose deescalation and investigated the expected toxicity rate at the MTD with the algorithm. In this paper, using the exact formulae derived by Lin and Shih (2), we study the expected toxicity rate at the MTD and the expected number of patients with toxicity and patients required when the hyperbolic tangent and the logistic functions are used as the unknown dose-toxicity curves. We consider the expected toxicity rate both without and with dose deescalation. No further study was done before in cases where dose level zero is chosen as the MTD. Since, in real practice, dose levels are lowered for adjustment and a new trial is conducted when dose level zero is decided as the MTD, we also incorporate this dose adjustment.

Original languageEnglish (US)
Pages (from-to)865-873
Number of pages9
JournalTherapeutic Innovation & Regulatory Science
Volume36
Issue number4
DOIs
StatePublished - 2002

Fingerprint

Clinical Trials, Phase I
Maximum Tolerated Dose
Neoplasms
Pharmaceutical Preparations

Keywords

  • Algorithm-based design
  • Dose finding studies
  • Maximum tolerated dose
  • Phase 1 cancer trials
  • Toxicity

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Public Health, Environmental and Occupational Health
  • Pharmacology (medical)

Cite this

An investigation of the traditional algorithm-based designs for phase 1 cancer clinical trials. / Kang, Seung Ho; Ahn, Chul W.

In: Therapeutic Innovation & Regulatory Science, Vol. 36, No. 4, 2002, p. 865-873.

Research output: Contribution to journalArticle

@article{e6b74e1693ef423a869cf08eb2a295c7,
title = "An investigation of the traditional algorithm-based designs for phase 1 cancer clinical trials",
abstract = "The primary aim of a phase 1 cancer clinical trial is to determine the maximum tolerated dose of a new drug. Although the continual reassessment method is shown to have better operating characteristics than traditional designs, traditional designs are still widely used in practice. Kang and Ahn (1) developed an algorithm to compute the exact distribution of the maximum tolerated dose (MTD) in traditional designs with dose deescalation and investigated the expected toxicity rate at the MTD with the algorithm. In this paper, using the exact formulae derived by Lin and Shih (2), we study the expected toxicity rate at the MTD and the expected number of patients with toxicity and patients required when the hyperbolic tangent and the logistic functions are used as the unknown dose-toxicity curves. We consider the expected toxicity rate both without and with dose deescalation. No further study was done before in cases where dose level zero is chosen as the MTD. Since, in real practice, dose levels are lowered for adjustment and a new trial is conducted when dose level zero is decided as the MTD, we also incorporate this dose adjustment.",
keywords = "Algorithm-based design, Dose finding studies, Maximum tolerated dose, Phase 1 cancer trials, Toxicity",
author = "Kang, {Seung Ho} and Ahn, {Chul W.}",
year = "2002",
doi = "10.1177/009286150203600415",
language = "English (US)",
volume = "36",
pages = "865--873",
journal = "Therapeutic Innovation and Regulatory Science",
issn = "2168-4790",
publisher = "SAGE Publications Inc.",
number = "4",

}

TY - JOUR

T1 - An investigation of the traditional algorithm-based designs for phase 1 cancer clinical trials

AU - Kang, Seung Ho

AU - Ahn, Chul W.

PY - 2002

Y1 - 2002

N2 - The primary aim of a phase 1 cancer clinical trial is to determine the maximum tolerated dose of a new drug. Although the continual reassessment method is shown to have better operating characteristics than traditional designs, traditional designs are still widely used in practice. Kang and Ahn (1) developed an algorithm to compute the exact distribution of the maximum tolerated dose (MTD) in traditional designs with dose deescalation and investigated the expected toxicity rate at the MTD with the algorithm. In this paper, using the exact formulae derived by Lin and Shih (2), we study the expected toxicity rate at the MTD and the expected number of patients with toxicity and patients required when the hyperbolic tangent and the logistic functions are used as the unknown dose-toxicity curves. We consider the expected toxicity rate both without and with dose deescalation. No further study was done before in cases where dose level zero is chosen as the MTD. Since, in real practice, dose levels are lowered for adjustment and a new trial is conducted when dose level zero is decided as the MTD, we also incorporate this dose adjustment.

AB - The primary aim of a phase 1 cancer clinical trial is to determine the maximum tolerated dose of a new drug. Although the continual reassessment method is shown to have better operating characteristics than traditional designs, traditional designs are still widely used in practice. Kang and Ahn (1) developed an algorithm to compute the exact distribution of the maximum tolerated dose (MTD) in traditional designs with dose deescalation and investigated the expected toxicity rate at the MTD with the algorithm. In this paper, using the exact formulae derived by Lin and Shih (2), we study the expected toxicity rate at the MTD and the expected number of patients with toxicity and patients required when the hyperbolic tangent and the logistic functions are used as the unknown dose-toxicity curves. We consider the expected toxicity rate both without and with dose deescalation. No further study was done before in cases where dose level zero is chosen as the MTD. Since, in real practice, dose levels are lowered for adjustment and a new trial is conducted when dose level zero is decided as the MTD, we also incorporate this dose adjustment.

KW - Algorithm-based design

KW - Dose finding studies

KW - Maximum tolerated dose

KW - Phase 1 cancer trials

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=84996260605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84996260605&partnerID=8YFLogxK

U2 - 10.1177/009286150203600415

DO - 10.1177/009286150203600415

M3 - Article

AN - SCOPUS:84996260605

VL - 36

SP - 865

EP - 873

JO - Therapeutic Innovation and Regulatory Science

JF - Therapeutic Innovation and Regulatory Science

SN - 2168-4790

IS - 4

ER -